Oramed Pharm (OJU1) Stock Price & Analysis

OJU1 Stock Chart & Stats

€3.73€0.04(1.09%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 3.73 - EUR 3.73
52-Week Range: EUR 1.88 - EUR 4.53
Previous Close: EUR 3.69
Volume: 0
Average Volume (3M): 77
Market Cap: EUR 153.08M
Enterprise Value: EUR 154.55M
Total Cash (Recent Filing): EUR 50.61M
Total Debt (Recent Filing): EUR 733.00K
Price to Earnings (P/E): 1.0
Beta: 0.55
Next Earnings: Jul 14, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Oral Delivery Platform

The proprietary platform is aimed at converting traditionally injected peptide therapies into oral medicines, addressing a meaningful administration barrier. If clinical development succeeds, this differentiated approach could support product value, broaden treatment convenience, and create a reusable foundation across multiple peptide programs.

Conservative Balance Sheet

Extremely low leverage gives Oramed greater financial flexibility than a highly indebted development-stage biotech. A sizable equity base can help preserve strategic options, reduce solvency pressure, and provide more capacity to fund research or partnerships while clinical programs remain in development.

Governance Continuity

Shareholder approval of the board, auditor, compensation framework, and future voting cycle supports continuity in governance over the coming periods. Stable oversight can help management maintain focus on the company’s development programs and execute its existing strategic direction.

Bears Say

Minimal Revenue Base

A minimal and inconsistent revenue base indicates that Oramed has not yet established commercial operating traction. This leaves the business dependent on successful development and eventual commercialization of its pipeline, making near-term financial performance less predictable and limiting internally generated resources.

Persistent Cash Burn

Persistent negative operating and free cash flow means current activities are not self-funding and that cash resources continue to be consumed. This raises the importance of disciplined capital allocation and increases the likelihood that future development may require additional financing or other funding actions.

Weak Core Profitability

Deeply negative EBIT shows that recent headline net income has not translated into stronger underlying operating economics. The gap between reported earnings and core profitability makes results less durable, increases earnings variability, and leaves the company without established operating leverage.

Oramed Pharm News

Oramed Pharm Shareholders Back Governance and Incentive Plan

Oramed Pharm ( ($ORMP) ) has issued an announcement. At its Annual Meeting of Stockholders held on September 15, 2026, Oramed Pharm shareholders re-elected all incumbent directors to serve until

1M ago8K ORMP

Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions

Oramed Pharm ( ($ORMP) ) has shared an announcement. On June 28, 2026, Oramed Pharmaceuticals’ board approved Fifth Amended and Restated Bylaws, effective June 25, 2026, revising procedures for stockholder

4M ago8K ORMP

Oramed to join Russell 2000 and 3000 indexes

Oramed (ORMP) Pharmaceuticals announced that it is set to join the U.S. small cap Russell 2000 and broad-market Russell 3000 Index at the conclusion of the 2026 Russell indexes semi-annual

4M agoORMP OJU1

Oramed Pharmaceuticals Delays Quarterly SEC Filing

Oramed Pharm ( ($ORMP) ) has released a notification of late filing. Oramed Pharmaceuticals Inc. has filed a Form 12b-25, notifying investors of a delay in submitting its Form 10-Q

5M agoORMP OJU1

Oramed Completes Oratech Sale and Strategic Lifeward Financing

Oramed Pharm ( ($ORMP) ) just unveiled an update. On March 25, 2026, Lifeward Ltd. completed its previously announced acquisition of Oramed’s wholly owned subsidiary Oratech Pharma, Inc., issuing Oramed

7M ago8K ORMP

Lifeward closes strategic partnership agreement with Oramed

Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company

7M agoLFWD ORMP

Lifeward receives shareholder approval to close on partnership with Oramed

Lifeward (LFWD) announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals

7M agoLFWD ORMP

Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal

The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2026, Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company, under which Oramed deferred

8M ago8K ORMP

Oramed Pharm pivots with Lifeward strategic platform deal

The latest update is out from Oramed Pharm ( ($ORMP) ). On January 12, 2026, Oramed Pharmaceuticals entered into a set of strategic agreements with Lifeward Ltd. under which Oramed

9M ago8K ORMP

Oramed and Lifeward sign strategic transaction

Oramed (ORMP) and Lifeward (LFWD) signed binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed’s proprietary

9M agoLFWD ORMP

Oramed Pharm Announces Dividend After Scilex Payment Gain

Oramed Pharm ( ($ORMP) ) has provided an update. On January 7, 2026, Oramed Pharmaceuticals reported receiving an $18 million payment from Scilex Holdings Inc., marking full satisfaction of obligations

9M ago8K ORMP

Oramed receives $18M payment from Scilex Holdings

Oramed (ORMP) Pharmaceuticals announced it has received an $18M payment from Scilex Holdings, representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed’s current returns to $118M

9M agoORMP OJU1

Oramed declares cash dividend payment of 25c per share

Oramed’s (ORMP) Board of Directors has approved a cash dividend payment of 25c per share to reward shareholders. The dividend will have an ex-dividend date of January 16, with disbursement

9M agoORMP OJU1

Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation

Oramed Pharm ( ($ORMP) ) just unveiled an update. On December 31, 2025, Oramed Pharmaceuticals Inc. announced that board member Leonard Sank notified the company of his intention to resign

10M ago8K ORMP

OJU1 FAQ

What was Oramed Pharm’s price range in the past 12 months?

Oramed Pharm lowest stock price was €1.88 and its highest was €4.53 in the past 12 months.

What is Oramed Pharm’s market cap?

Oramed Pharm’s market cap is €153.08M.

When is Oramed Pharm’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Oramed Pharm’s earnings last quarter?

Oramed Pharm released its earnings results on Jul 15, 2026. The company reported €2.471 earnings per share for the quarter, beating the consensus estimate of €0.385 by €2.086.

Is Oramed Pharm overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Oramed Pharm pay dividends?

Oramed Pharm does not currently pay dividends.

What is Oramed Pharm’s EPS estimate?

Oramed Pharm’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oramed Pharm have?

Oramed Pharm has 41,597,355 shares outstanding.

What happened to Oramed Pharm’s price movement after its last earnings report?

Oramed Pharm reported an EPS of €2.471 in its last earnings report, beating expectations of €0.385. Following the earnings report the stock price went up 0.439%.

Which hedge fund is a major shareholder of Oramed Pharm?

Currently, no hedge funds are holding shares in DE:OJU1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oramed Pharm Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Oramed Pharm

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

Oramed Pharm (OJU1) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	9	4	9
Technical Analysis	2	4	4
Moving Averages	7	0	5

Technical Analysis >

Similar Stocks

Stocks similar to DE:OJU1
Company	Price & Change	Follow
WHWKWhitehawk Therapeutics
ALXOALX Oncology Holdings
SPRBSpruce Biosciences

Compare DE:OJU1 Stocks >

Ownership Overview

25.16% Insiders
2.35% Mutual Funds
0.71% Other Institutional Investors
67.29% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft